» Articles » PMID: 35917826

Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography

Overview
Journal Rofo
Publisher Thieme
Date 2022 Aug 2
PMID 35917826
Authors
Affiliations
Soon will be listed here.
Abstract

Despite the high prevalence and mortality of lung cancer and proven effectiveness of low-dose computed tomography (LDCT) to reduce mortality, Germany still lacks a national screening program. The German Institute for Quality and Efficiency in Health Care (IQWiG) and the Federal Office for Radiation Protection (BfS) both published positive scientific evaluations recommending a quality-controlled national screening program. IQWiG underlined the importance of a clear risk definition, integrated smoking cessation programs, and quality assurance, highlighting the necessity of procedural optimization.In the HANSE study, former and current smokers aged 55-79 years are assessed for their lung cancer risk by the NELSON and PLCO risk scores. 5000 high-risk participants, defined as PLCO 6-year risk ≥ 1.58 % or fulfilling NELSON risk inclusion criteria, will be screened by LDCT at baseline and after 12 months. Lung nodules are analyzed by a modified Lung-RADS 1.1 score of the HANSE study, and values of emphysema and coronary calcium are determined and randomly reported to the participants. 7100 low-risk participants serve as a control. All patients are followed-up for up to 10 years. The sensitivity and specificity of the two risk assessments and LDCT screening, effects of the randomized LDCT reporting, efficiency of lung nodule management, and several other factors are assessed to analyze the success and quality of the holistic screening program.The HANSE study is designed as a holistic lung cancer screening study in northern Germany to answer pressing questions for a successful implementation of an effective German lung cancer screening program. · HANSE is designed to address pressing questions for the implementation of lung cancer screening in Germany.. · HANSE compares NELSON and PLCOM2012 risk assessments for optimal definition of the high-risk group. . · HANSE integrates cardiac calcium and pulmonary emphysema scoring in a holistic screening approach.. CITATION FORMAT: · Vogel-Claussen J, Lasch F, Bollmann B et al. Design and Rationale of the HANSE Study: A Holistic German Lung Cancer Screening Trial Using Low-Dose Computed Tomography. Fortschr Röntgenstr 2022; 194: 1333 - 1345.

Citing Articles

Comparison of AI software tools for automated detection, quantification and categorization of pulmonary nodules in the HANSE LCS trial.

Kondrashova R, Klimes F, Kaireit T, May K, Barkhausen J, Stiebeler S Sci Rep. 2024; 14(1):27809.

PMID: 39537690 PMC: 11561337. DOI: 10.1038/s41598-024-78568-z.


Strengthening lung cancer screening in Europe: fostering participation, improving outcomes, and addressing health inequalities through collaborative initiatives in the SOLACE consortium.

Kauczor H, von Stackelberg O, Nischwitz E, Chorostowska-Wynimko J, Hierath M, Mathonier C Insights Imaging. 2024; 15(1):252.

PMID: 39436577 PMC: 11496428. DOI: 10.1186/s13244-024-01814-5.


Non-invasive surrogate markers of pulmonary hypertension are associated with poor survival in patients with cancer.

Cekay M, Arndt P, Franken J, Wilhelm J, Pullamsetti S, Roller F BMJ Open Respir Res. 2024; 11(1).

PMID: 39179271 PMC: 11344493. DOI: 10.1136/bmjresp-2023-001916.


ERS International Congress 2023: highlights from the Thoracic Oncology Assembly.

Catarata M, Creamer A, Dias M, Toland S, Chaabouni M, Verbeke K ERJ Open Res. 2024; 10(1).

PMID: 38410708 PMC: 10895436. DOI: 10.1183/23120541.00860-2023.


Important steps towards a big change for lung health: a joint approach by the European Respiratory Society, the European Society of Radiology and their partners to facilitate implementation of the European Union's new recommendations on lung cancer....

Ward B, Koziar Vasakova M, Cordeiro C, Yorgancioglu A, Chorostowska-Wynimko J, Blum T ERJ Open Res. 2023; 9(3).

PMID: 37228272 PMC: 10204812. DOI: 10.1183/23120541.00026-2023.

References
1.
Grundy S, Stone N, Bailey A, Beam C, Birtcher K, Blumenthal R . 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018; 139(25):e1082-e1143. PMC: 7403606. DOI: 10.1161/CIR.0000000000000625. View

2.
Tammemagi M, Katki H, Hocking W, Church T, Caporaso N, Kvale P . Selection criteria for lung-cancer screening. N Engl J Med. 2013; 368(8):728-36. PMC: 3929969. DOI: 10.1056/NEJMoa1211776. View

3.
Agatston A, Janowitz W, HILDNER F, Zusmer N, VIAMONTE Jr M, Detrano R . Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990; 15(4):827-32. DOI: 10.1016/0735-1097(90)90282-t. View

4.
Herth F, Reinmuth N, Wormanns D, Antoch G, Biederer J, Vogel-Claussen J . [Joint Statement of the German Radiological Society and the German Respiratory Society on a Quality-Assured Early Detection Program for Lung Cancer with Low-dose CT]. Pneumologie. 2019; 73(10):573-577. DOI: 10.1055/a-0984-8367. View

5.
Lynch D, Austin J, Hogg J, Grenier P, Kauczor H, Bankier A . CT-Definable Subtypes of Chronic Obstructive Pulmonary Disease: A Statement of the Fleischner Society. Radiology. 2015; 277(1):192-205. PMC: 4613878. DOI: 10.1148/radiol.2015141579. View